Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders

Psychiatric Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. Psychiatric Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.

This is the first volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, and is also available for purchase individually.

Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery processCritical evaluation of animal and translational models improving transition from drug discovery and clinical developmentEmphasizes what results mean to the overall drug discovery processExplores issues in clinical trial design and conductance in each therapeutic areaPsychiatric Disorders is available for purchase individually.

Preface to Psychiatric Disorders Volume:
What Do You Mean By “Translational Research”? An Enquiry through Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders
Robert A McArthur and Franco Borsini

1. Mark J. Millan. The Discovery and Development of Pharmacotherapy for Psychiatric Disorders: A Critical Survey of Animal and Translational Models, and Perspectives for their Improvement

2. L. Winsky et al. Drug Discovery and Development Initiatives at the National Institute of Mental Health: From Cell-Based System to Proof of Concept

3. J. McEvoy and Freudenreich. Issues in the Design and Conductance of Clinical Trials

4. Klaus A. Miczek. Challenges for Translational Psychopharmacology Research – The Need for Conceptual Principles

5. T. Steckler et al. Developing Novel Anxiolytics: Improving Preclinical Detection and Clinical Assessment

6. D. Joel et al. Animal Models of Obsessive-Compulsive Disorder: From Bench to Beside Via Endophenotypes and Biomarkers

7. J. Cryan et al. Developing More Efficacious Antidepressant Medications:
Improving and Aligning Preclinical and Clinical Assessment Tools

8. D. Jones et al. Developing New Drugs for Schizophrenia: From Animals to the Clinic

9. C. Large et al. Developing Therapeutics for Bipolar Disorder (BPD): From Animal Models to the Clinic

10. R. Tannock et al. Towards a Biological Understanding of ADHD and the Discovery of Novel Therapeutic Approaches

11. J. Bartz et al. Preclinical Animal Models of Autistic Spectrum Disorders (ASD)

12. S. Doran et al. Translational Models of Sleep and Sleep Disorders

Epilogue:
Translational Models for the 21st century: Reminiscence, Reflections and Some Recommendations
Paul Willner, Franco Borsini, and Robert A McArthur